The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.
John P. Neoptolemos, MA, MB, BChir, MD
Advertisement
Articles by John P. Neoptolemos, MA, MB, BChir, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC
2
ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma
3
How the Landscape of GI Oncology is Evolving: A 2026 ASCO Preview
4
Prescribing Exercise in Oncology: Moving Beyond “Good Luck”
5